Abstract: SH-SY5Y human neuroblastoma cells express muscarinic M 3 receptors as well as insulin receptors, thus offering the opportunity to investigate possible cross-talk following activation of two distinct intracellular signal transduction pathways that convert the precursor phosphatidylinositol (P1) to its 3' phosphate or its 4' phosphate, respectively. In this study, the effect of carbachol on insulin-stimulated P1 3-kinase (P13K) activity was examined in SH-SY5Y cells. Insulin addition to the cell medium induced a 10-26-fold increase in anti-phosphotyrosine-immunoprecipitable P13K activity. Preincubation with 1 mM carbachol inhibited the insulin-stimulated P13K activity in a time-dependent manner, with half-maximal and maximal inhibition times of 4 and 15 mm, respectively. Atropine blocked the inhibitory effect of carbachol. Although carbachol did not change the amount of 85-kDa subunit protein regulatory unit associated with tyrosinephosphorylated proteins, either in control or in insulinstimulated cells, it appears to decrease the amount of associated 11 0-kDa catalytic subunit protein in the latter instance. Because P13K activity from SH-SY5Y cells has been shown to be inhibited in vitro in the presence of cytidine diphosphodiacylglycerol (COP-DAG) or phosphatidate(PA), we examined the presence of these lipids in SH-SY5Y cells that had been treated with carbachol. Formation of both lipids was increased in a time-dependent manner following carbachol addition, and their increased levels are proposed to account for the observed in vivo inhibition of P13K. Addition of the cell-permeable homologue didecanoyl-CDP-OAG to intact cells inhibited insulin-stimulated P13K activity up to 75%, with an 1050 of 0.5~tM, a result that further supports a proposed lipidmediated inhibition of P13K. Exogenously added didecanoyl-PA, however, did not affect P13K activity. The possibility that stimulation of the P1 4-kinase-mediated signal transduction pathway leads to down-regulation of the P13K-mediated signal transduction pathway in vivo, via inhibition of P13K by CDP-DAG or by other consequences of phosphoinositidase C-linked receptor activation, is discussed. Key Words: Carbachol-lnsulin--Phosphatidylinositol 3-kinase-Cytidine diphosphodiacylglycerol-Phosphatidate-SH-SY5Y neuroblastoma cells. J. Neurochem. 67, 1245-1251 (1996).
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Phosphatidylinositol (P1) 3 -ki nase (P13K) mediates a central downstream signal transduction route for vanous growth factors, including cytokines, epithelial growth factor, platelet-derived growth factor, insulin, insulin-like growth factors (lGFs), and nerve growth factor (NGF) (Parker and Waterfleld, 1992) , and is permissive for several cellular responses, including liiitogenesis (Rodriguez-Viciana et al., 1994) , translocation of glucose transporters (Clarke et al., 1994) , and differentiation (Carter and Downes, 1993) . The enzyme is able to phosphorylate P1, P1 4-phosphate (PT4P), and Pt 4,5-bisphosphate [Pl(4,5)P~J on the 3' position of the inositol ring in vitro, yielding in each instance the 3-phosphate of the corresponding lipid (Panayotou and Waterfield, 1992; Parker and Waterfield, 1992) . In vivo, PI(4,5)P2 is the favored substrate (Hawkins et al., 1992) . The mechanism by which insulin activates P13K involves induction of insulin receptor tyrosine kinase activity followed by tyrosine phosphorylation of insulin receptor substrate I (IRS-I). Tyrosine-phosphorylated residues within IRS-I then associate with specific src homology domains of various target proteins, including P13K (Myers et al., 1994) . The recruitment of P13K holoenzyme [containing both the 85-kDa (p85) regulatory subunit and the 1 lO-kDa (p110) catalytic subunit] results in the enzyme's activation. p85 is thought to act as an adapter protein that couples the p110 catalytic subunit to tyrosine phosphoproteins via an SF12 domain (Hu and Schlessinger, 1994) .
In the present study we used SH-SYSY human neuroblastoma cells, which express insulin receptors (Mattsson et al., 1990) as well as muscaninic M 3 receptors (Offermanns et al., 1993) , to examine P13K activity following exposure of the cells to both insulin and carbachol. This investigation was prompted by a prior study in which we demonstrated that phosphatidate (PA) and cytidine diphosphodiacylglycerol (CDP-DAG) each block P13K in vitro (Lavie and Agranoff, 1996) . These two lipids are sequential biosynthetic precursors of PT, the common lipid substrate for both P13K and P1 4-kinase (P14K) (Fisher et al., 1992) . It was furthermore known that labeled CDP-DAG levels are elevated during carbachol-sti mulated phosphoinositide turnover cycle [which uses the P14K pathway in these cells (Heacock et al., 1993) ]. The question was thus raised of whether or not ligand-stimulated breakdown of PI(4,5)P2 and its associated resynthesis via PA and CDP-DAG would affect stimulation of the P13K-mediated pathway in vivo. Because insulin induces a mitogenic response and enhances neurite formation in SH-SY5Y cells (Recio-Pinto and Ishii, 1988; Mattsson et al., 1990) , it was chosen for investigation of the possible effects of carbachol-stimulated activation of the P14K pathway on the P13K pathway in these cells.
The present results indicate that elevated intracellular CDP-DAG content resulting from stimulated PI(4,5)P2 breakdown may contribute to regulation of the P13K-directed signal transduction pathway in vivo. During the course of these studies, it was found that carbachol addition to insulin-stimulated cells leads to selective loss of p110 from the phosphotyrosine immunocomplex, indicating a possible additional mechanism for interaction of the two signal transduction pathways.
EXPERIMENTAL PROCEDURES

Materials
ATP, bovine serum albumin, carbachol, insulin from bovine pancreas, leupeptin, aprotinin, and PT from bovine liver were purchased from Sigma (St. Louis, MO, U.S.A.). Didecanoyl-PA was the product of Serdary Research Labs (London, Ontario, Canada). Didecanoyl cytidine diphosphodiacylglycerol (CIO-CDP-DAG) was the gift of A. K. Hajra. [y-32P1ATP (3,000 Ci/mmol) and [3H]cytidine (30 Ci/mmol) were from DuPont NEN(Wilmington, DE, U.S.A.). Carderfree 32P~was purchased from ICN Pharmaceuticals (Costa Mesa, CA, U.S.A.). Silica gel 60 TLC plates were from Merck (Darmstadt, Germany). Dulbecco's modified Eagle's medium, fetal bovine serum, and protein A-agarose were purchased from GibcoBRL (Gaithersburg, MD, U.S.A.). Anti-rat P13K (anti-p85) and anti-phosphotyrosine (monoclonal IgG2bk) antibodies were from Upstate Biotechnology (Lake Placid, NY, U.S.A.). Anti-pI 10 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.).
FIG. 1.
Insulin and NGF stimulate P13K activity in anti-phosphotyrosine immunoprecipitates of SH-SY5Y cells. Cells were grown as described in Experimental Procedures. Insulin (100 nM) or NGF (100 nM)was added to the medium and incubated for the indicated times at 37°C.Lysates were immunoprecipitated with anti-phosphotyrosine antibodies, and P13K activity was measured as described in Experimental Procedures. Autoradiographs of the TLC of PIP are from one of three experiments that gave similar results.
Cell culture
SH-SY5Y human neuroblastoma cells (passages 60-80) were grown in Dulbecco's modified Eagle's supplemented with 10% fetal bovine serum at 37°Cin a humidified atmosphere containing 10% CO 2. For all the experiments using effectors (insulin, carbachol. etc.), cells were preincubated for 24 h in Dulbecco's modified Eagle's medium supplemented with 0.1% bovine serum albumin.
Immunoprecipitation of P13K activity from stimulated cells using anti-phosphotyrosine antibodies
Cells were grown in 150-mm-diameter dishes. Effectors were directly added to the medium, and the cells were incubated for the indicated times at 37°C.After hormonal treatinent, the medium was aspirated, and the cells were washed twice with 15 ml of ice-cold phosphate-buffered saline (PBS; pH 7.4) before addition of 1 ml of buffer B [137mM NaCI, 20 mM Tris-HCI (p1-I 8.0), 1 mM EDTA, 1 mM MgCI2, 1 mM CaC12, 10% glycerol. 1% Nonidet P-40. 10 eg/mlof leupeptin, 2 pg/mI of aprotinin. 1 mM phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate]. The cells were scraped free from the dishes and centrifuged at 6,000 g for 10 mm in a 15-ml conical polystyrene centrifuge tube (Sardstet). The resulting supernatant was incubated overnight at 4°Cwith 5 pg per tube of anti-phosphotyrosine antibodies, followed by addition of protein A-agarose beads for 2 h. Immune complexes bound to the beads were washed three times with cold PBS (pH 7.4) containing 1% Nonidet P-40, twice with PBS containing 0.5 M LiCI and 0.1 M Tris-1-ICI (pH 7.5), and twice with 10 aiM Tris-l-ICl (pH 7.5) containing 0.1 M NaCI and 1 mM EDTA.
P13K assay
The reaction mixture for measuring P13K activity contained 100 p1 of the enzyme and 50 pl of P1 micelles that were prepared by sonicating 800 pg of Pt in 1 ml of 20mM HEPES buffer (pH 7.6) containing 1 mM EDTA for 45 s (Kontes sonicator with a microtip probe). The mixture was preincubated for 15 mm at room temperature. and the reaction was j. Neurochem., Vol. 67, No. 3, 1996 started by addition of 50 pl of 40 mM MgCI 2 containing 200 pM [y- tP]ATP (20 pCi per assay). The reaction was terminated after 15 mm by addition of 750 p1 of ice-cold CF1C1~/methanol /2 M FICI (20:40:0.5 by volu me) followed by 250 pl of chloroform and 250 p.I of 2 M HC1. The resulting organic phase and the interface were extracted with an equal volume of methanol/U. 1 M EDTA (1:0.9 vol/vol). The organic phase was dried, resuspended in 25 p.l of chloroform/methanol (1:1 vol/vol), and spotted on a TLC plate that was precoated with 1% potassium oxalate. The plate was developed in CHCI 2/methanol/water/7.7 M NH4OH (60:47:11.3:2 by volume) (Scrunian et al.. 1991) .~2 P-Labeled P1 3-phosphate (PI3P) was visualized by autoradiography and compared with iodine-stained PT phosphate marker, for which PI4P was used. Radioactivity in this spot was quantified as described in Experimental Procedures. Although PI3P and PI4P are not separated by this procedure, the possibility that P14K activity was present was excluded on the basis of susceptibility to wortmannin and to Nonidet P-40 detergent.
Immunoblotting of the p85 subunit of P13K
Cells, treated with various efiectors, were lysed, followed by immunoprecipitation with anti-phosphotyrosine antibodies as described above. After washing, immune complexes were resolved on 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were transferred to nitrocellulose paper and analyzed for the presence of the p85 by protein iminunoblot, using anti-p85 antiserum. Bound antibodies were visualized by an enhanced chemiluininescence (ECL) detection system, using horseradish peroxidase conjugated to anti-rabbit IgG as the secondary antibody (Amersham). In a separate series of experiments, gels were reprobed with anti-p 1 10 antibody.
Radiolabeling studies
Cells were labeled with either~P, or [3Hlcytidine in oxygenated buffer A (142 mM NaCI, 5.6 mM KCI, 2.2 mM CaCl 2, 3.6 mM NaHCO2, I mM MgC12, 5.6 mM glucose, and 30 mM HEPES, pH 7.4). To label PA, cells grown in 60-mm-diameter culture dishes were washed twice with buffer A and preincubated in 5 ml of the same buffer containing 20 pCi of 32P 1 per dish for 10 mm at 37°C.To label CDP-DAG, cells were washed as above and incubated in 5 ml of buffer A containing 10 pCi of I H]cytidine per dish I h at 37°C.Following addition of the effectors for various time points, reactions were terminated on ice by aspirating the medium and adding 1 ml of ice-cold methanol/I M 1-ICI. The cells were scraped free from the dishes and transferred to glass test tubes. Lipids were extracted from the cell pellet by adding 1 ml each of water and chloroform, followed by vortex-mixing. The lower chloroform phase was dried with a Speed Vac and resuspended in 25 pl of chloroform! methanol (1:1 vol/vol). Lipids extracts were spotted on a 20-~2(3-cm TLC plate and were developed in a CHCI,/ CH,OH/acetic acid/acetone/water (40:13:12:15:8 by volume) solvent system. The plate was subjected to autoradiography, and the radioactive bands were identified by cochromatography with authentic standards. TLC spots of the radioactive lipids were scraped off into counting vials, and radioactivity was determined by liquid scintillation counting.
RESULTS
Stimulation of P13K activity associated with antiphosphotyrosine immunoprecipitates in SH-SY5Y cells is induced by insulin and NGF
Activation of P13K is generally correlated with an increase in the amount of P13K activity that can he immunoprecipitated with anti-phosphotyrosine antibodies. We found that in SH-SY5Y cells, insulin and NGF are each able to induce such an enzyme activation. As shown in Fig. I , insulin induced a rapid increase in anti-phosphotyrosine-precipitable P13K activity, which was clearly visible by I mm and was maximal by 5 mm. The response was transient and decreased thereafter (data not shown). Although the kinetics of stimulation by NGF were very similar, NGF's potency was much lower (threefold stimulation, compared with 20-fold).
Carbachol inhibits insulin-stimulated P13K activity
We examined the effect of the muscarinic ligand carbachol on the activation of P13K by insulin. Pretreatment of SH-SYSY cells with 1 mM carbachol for 30 mm markedly reduced the elevation in PI3P content produced by P13K from insulin-stimulated cells (Fig.  2) . PI3P content was also lower compared with control basal levels after treatment with carbachol alone. The inhibitory effect elicited by carbachol was blocked by preincubation of the cells with the muscaninic antagonist atropine, demonstrating that the effect of carbachol was receptor mediated. Figure 3 shows that the inhibition of insulin-induced P13K activity by carbachol is time dependent. As preincubation time increased, enzyme-stimulated activity decreased, with half-maximal and maximal times of 4 and IS mm, respectively.
Investigation of possible mechanisms by which carbachol inhibits insulin-stimulated P13K activity
Because P13K is activated in insulin-stimulated cells by the binding of its p85 to tyrosine-phosphorylated
FIG. 2. Carbachol inhibits insulin-stimulated P13K activity. Cells
were preincubated for 10 mm without or with atropine (10 pM) and then for an additional 30 mm in the absence or presence of 1 mM carbachol, followed by addition of 100 nM insulin for 5 mm. Cellular extracts were then reacted with anti-phosphotyrosine antibodies and assayed for P13K activity as described in Experimental Procedures. Carbachol produced an 87% decrease in this experiment, somewhat higher than the average inhibition seen in three experiments (56%).
FIG. 3. Time dependence of carbachol inhibition of insulin-stim-
ulated P13K activation. Cells were treated with or without (1 mM) carbachol for the indicated times and then for an additional 5 mm with 100 nM insulin, as indicated. Anti-phosphotyrosine immunoprecipitates were assayed for P13K activity as described in Experimental Procedures. The phosphorylated lipid products were separated by TLC, and the corresponding P1 phosphate band was scraped into vials and counted for radioactivity. P13K activity is calculated as a percentage of insulin-stimulated, uninhibited kinase activity (100% = 7,091 ± 430 cpm). Data are mean ±SD (bars; half the range) values of duplicate determinations and are typical of three experiments.
proteins, we examined the possibility that carbachol interferes directly with this interaction. Cells were treated with carbachol and/or insulin for 30 and 5 mm, respectively. Whole cell lysates were then subjected to immunoprecipitation with anti-phosphotyrosine antibodies, and the immunoprecipitates were analyzed by western blotting with anti-p85 antibodies. As shown in Fig. 4 , p85 association with tyrosine-phosphorylated proteins is greatly enhanced in cells treated with insulin. Carbachol affected neither the control level of p85 nor the insulin-stimulated association of p85 with tyrosine-phosphorylated proteins (lane 4). The tentative conclusion that the observed inhibitory effect of carbachol on insulin-induced P13K activation does not involve changes in binding of the heterodimer to tyrosine-phosphorylated protein was, however, challenged by further studies in which such gels were reprobed with anti-p 1 10 antibodies. In contrast to the lack of effect seen on p85 binding, a significant decrease (54%) in amount of anti-pI lO-immunoreactive material in insulin-stimulated cells was seen in the presence of carbachol, as is further addressed in Discussion.
Because CDP-DAG and PA inhibit SH-SY5Y cellderived P13K activity in vitro (Lavie and Agranoff, 1996) , it was of interest to examine the possibility that a carbachol-induced increase in CDP-DAG content could contribute to our in vivo findings. We first characterized the time course by which carbachol stimulates the formation of CDP-DAG and PA in SH-SY5Y cells. To assess changes in PA level, cells were incubated briefly with 32P~before addition of carbachol. The time course of labeled PA accumulation was then followed for 30 mm. As shown in Fig. 5 , labeled PA content is dramatically elevated as early as 1 mm after
FIG. 4. Detection of P13K in anti-phosphotyrosine immunopre-
cipitates by western blotting. Cells were treated for 30 mm with or without 1 mM carbachol and then for an additional 5 mm with or without 100 nM insulin, as indicated. The cellular extracts were immunoprecipitated with anti-phosphotyrosine antibodies, subjected to 7.5% SDS-PAGE, and then immunoblotted, using anti-p85 antibodies, as described in Experimental Procedures. The prominent spots above the 45-kDa mark represent lgGs. I. Neurochm'mrm., Vol. 67, No.3, 1996 within 3 mm of incubation and is maximal within 15 mm. The decrease in [ 3H]CDP-DAG level evident by 30 mm of incubation with carbachol is most likely due to further metabolism of CDP-DAG, primarily to P1. The elevation in [32P1PA content precedes that of LHICDP-DAG, reflecting the biosynthetic sequence in P1 resynthesis after carbachol-stimulated breakdown of Pl(4,5)P 7. To test directly the possibility that CDP-DAG is inhibiting P13K activity in vivo, we used C10-CDP-DAG (Benjamins and Agranoff, 1969) . Cells were preincubated for 1 h without or with given concentrations of C10-CDP-DAG and then stimulated with insulin for 5 mm. As shown in Fig. 6 , a 26-fold stimulation of PI3P formation by insulin was half-maximally reduced by 0.S ,uM C10-CDP-DAG and was maximally blocked at 10 p.M. These values are very close to the ICS() value (6 pM) required for inhibition of P13K by CDP-DAG in an in vitro assay system (Lavie and Agranoff, 1996) . Addition of C10-PA (0.01-100 pM), however, did not affect P13K activity (data not shown).
DISCUSSION
P13K participates in various signal-regulated cell processes induced by mitogenic growth factors and neurotrophic factors (Panayotou and Waterfield, 1992; Parker and Waterfield, 1992; Carter and Downes, 1993; Myers et al., 1994) . Stimulation of P13K activity by insulin in SH-SY5Y neuroblastoma cells resembles that observed with insulin in several other cell preparations, including Chinese hamster ovary cells (Ruderman et al., 1990) , adipocytes (Shepherd et al., 1995) , and rat liver and skeletal muscle (Folli et al., 1992) . and is associated with an increase in anti-phosphotyrosine-immunoprecipitable activity. It is generally accepted that insulin induces an association of the enzyme with tyrosyl-phosphorylated Tyr-Met-X-Met or Tyr-X-X-Met motifs in IRS-I, which increases on insulin stimulation, without an apparent increase in amount of tyrosyl-phosphorylated P13K (Sung and Goldfine, 1992; Myers et al., 1994) . Although there are alternative possible mechanisms for insulin-induced increases in P13K activity (Carter and Downes, 1993; Myers et al., 1994) , the present results indicate that association with IRS-I also occurs in SH-SY5Y cells. Western blots of insulin-treated cells with anti-P13K antibodies revealed a dramatic increase in the amount of P13K associated with an anti-phosphotyrosine-immunoprecipitable complex, indicating that the enzyme is associated with tyrosine-phosphorylated proteins in viva. In accordance with the finding, P13K activity measured in anti-phosphotyrosine immunoprecipitates was elevated 10-26-fold in insulin-stiniulated cells. In contrast, SH-SY5Y cell P13K protein and activity immunoprecipitated with anti-PI3K antibodies were not measurably affected by insulin treatment (data not shown), in agreement with what has been found in rat HTC cells (Sung and Goldfine, 1992) . These results also indicate that the insulin-regulated P13K activity present in anti-phosphotyrosine immunoprecipitates accounts for only a minor portion of cellular P13K.
Insulin's principal physiological role in liver and muscle is readily understood, but this is less clear for the nervous system. Receptors for insulin and IGFs arc present in various brain regions. and agonist binding leads to increased glucose, uridine, and thymidine uptake, as well as increased ornithine decarboxylase activity (Dc Pablo and Dc Ia Rosa, 1995) . Insulin receptors are present also in the SFI-SY5Y human neuroblastoma cell line and are known to induce mitogenesis and neurite formation (Recio-Pinto and Ishii, 1988; Mattsson et al., 1990) . Although the data indicate that P13K activation can mediate insulin signal transduction in a brain-derived cell line, it remains to be demonstrated that this insulin-stimulated activity in SF1-SYSY cells is a component of a mechanism whereby insulin exerts its neurotrophic effects on the CNS (Dc Pablo and Dc Ia Rosa, 1995) . It should also be noted that some of the insulin-induced P13K activity measured in the present study may be mediated by IGF receptors, as IGF receptors are present in SH-SY5Y cells (Mattsson et al.. 1990 ) are known to cross-react with insulin receptors (Recio-Pinto and Ishii, 1988) and to activate P13K (Dc Pablo and Dc Ia Rosa, 1995) . SH-SY5Y cells have been investigated extensively in regard to their muscarinic (Ms) acetylcholine receptors, which on activation stimulate phosphoinositide turnover (including release of DAG and inositol 1,4.5-trisphosphate, followed by PA, and CDP-DAG increases, protein kinase C activation, and elevation in intracellular [Ca~I . In addition to possible roles in prostanoid production and catecholamine release in neurons (Abdel-Latif, 1986) , muscarinic receptors have been linked, depending on the cell type examined, to increases (Gutkind et al., 1991) and decreases (Conklin et al., 1988) in mitogenesis. Conklin et al. (1988) have found that carhachol caused a marked inhibition of thymidine incorporation into A9 L cells transfected with M 1 and M~muscarinic receptors, which could be blocked by atropine. Our finding that P13K activation following insulin addition to intact cells is inhibited by carhachol raised the possibility that the inhibition of mitogenesis by carbachol reflects its inhibition of insulin-induced P13K activity.
These observations led us to study the nature of carbachol's action on the insulin signal to activate P13K. Receiit studies implicate tyrosine phosphorylation as both an initiator amid a possible consequence of muscarinic receptor-mediated P1 hydrolysis. Offerrnanns et al. (1993) have found that stimulation of muscarinic receptors increased tyrosine phosphorylatmon in SH-SY5Y cells. Thus, we investigated whether or not the tyrosine phosphorylation mechanism of insulin-induced activation of P13K is altered on carbachol addition. We found that carbachol, either added alone or in the presence of insulin, did not change the amount of P13K p8S associated with tyrosine-phosphorylated proteins. The availability of anti-p 110 antibody during the course of these experiments prompted us to investigate the possibility that carbachol decreases the insulin-stimulated increase in the amount of pl 10 that is associated with the phosphotyrosine immunocomplex. Unlike the result obtained with anti-p85 shown in Fig.  4 , we found a marked decrease in amount of bound p110. Because pl 10 is believed to bind to SH2 domains of p85 (Hu and Schlessinger, 1994) , it may be that carbachol selectively dissociates the former from the imrnunocornplex. It is unclear at present whether this represents an independent consequence of activation of the muscarinic receptor or whether the inferred dissociation of the P13K heterodimer is a consequence of CDP-DAG binding in vivo.
We investigated the effects of exogenously added CDP-DAG and PA, as we recently found that these phospholipid intermediates of the ligand-stimulated phosphoinositide cycle are capable of inhibiting P13K activity in vitro (Lavie and Agranoff, 1996) . We show here that the level of these lipids in intact SFI-SYSY cells is increased on carhachol addition. In accordance with previous studies (Thompson and Macdonald, 1976: Lee ci al., 1991) , the calculated intracellular concentrations of CDP-.DAG and PA after carbachol stimulation (Lavie and Agranoff, 1996) would seem to suffice for potential in vivo regulation of P13K activity. Addition of the membrane-permeable analogue C1 CDP-1)AG to cells bypasses carbachol-mediated receptor activation and results in a similar extent of inhibition as does carbachol. The lack of' an analogous effect of added PA may reflect its lesser in vitro inhibitory action relative to CDP-DAG. failum'e to enter Ilie cells, or its rapid breakdown. CDP-DAG amid its analogues appear to enter cells intact (Turcotte Ct al.. 1980) . It should be noted that interpretation of these in vivo experiments on the basis of in vitro effects of CDP-DAG do not take into account issues of intracellular compartmentation. Because the levels of CDP-DAG in SH-SY5Y cells may vary with the inositol concentration in the cultui-e m'nediuni and may be further modified in the presence of Li" (Stuhhs and Agranoff, 1993) . it will he of interest to examine further P13K activity under these various conditions. Preliminary results (authors' unpublished data) indicate that constitutive levels of P13K are decreased under conditions of low medium levels of inositol in the presence of Li but no effect is seen on insulin stimulation.
In a prior study (Lavie and Agranoff, 1996) , we demonstrated that CDP-DAG does not compete with PI3K's cosubstrates, P1 or ATP. Possible effects of higher inositides of the P1 3-and P1 4-series wider conditions of hormonal stimulation have not been cxamimied. Of relevance is that Pt 3.4,5-trisphosphate has been demonstrated to block P13K in 1-hR cells (Rameh et al.. 1995 ). The precise mechanism whereby CDP-DAG (or possibly PA) inhibits P13K is unknown, nor is it presently known whether the apparent dissociation of the P13K heterodimer seen in insulin-stimulated cells preincubated with carbachol is mediated via increased levels of CDP-DAG or by an independent mechanism. Nevertheless, the finding that such inhibition occurs in viva gives further credence to the hypothesis that stimulation of the P14K-mediated pathway, whereby the intracellular messengers inositol 1,4,5-trisphosphate amid DAG are generated. may inhibit the P13K-mediated signal transduction pathway. somewhat paradoxically, via increases in levels of metabolic precursors of P1, the common substrate of both P13K and P14K.
